Atlas Trials

Solid Cancers

42 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Solid Cancers

RecordFirmDate
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (NCT05396300)Weijia Fang, MD2022-05-25
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study (NCT05228106)Centre de recherche du Centre hospitalier universitaire de Sherbrooke2022-01-21
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy (NCT03514368)Institut Claudius Regaud2018-05-28
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors (NCT02323191)Hoffmann-La Roche2015-01-19
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02174172)Hoffmann-La Roche2014-08-18
Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer (NCT01820299)Medical University of South Carolina2013-03-01
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors (NCT01301716)Genentech, Inc.2011-09-01
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (NCT01332604)Genentech, Inc.2011-07-01
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (NCT01296555)Genentech, Inc.2011-03-16
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists (NCT01209143)Genentech, Inc.2010-11-01
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma (NCT01226277)Genentech, Inc.2010-10-01
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors (NCT01139723)Genentech, Inc.2010-06-01
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT01106599)Genentech, Inc.2010-04-01
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors (NCT01090960)Genentech, Inc.2010-03-01
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors (NCT01075464)Genentech, Inc.2010-02-01
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists (NCT00968981)Genentech, Inc.2009-09-01
A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors (NCT00954642)Genentech, Inc.2009-08-01
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer (NCT00927589)Genentech, Inc.2009-07-01
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors (NCT00909740)Genentech, Inc.2009-05-22
A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors (NCT00747734)Genentech, Inc.2008-09-01
A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors (NCT01068977)Genentech, Inc.2007-08-01
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies (NCT00977067)Genentech, Inc.2007-06-01
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors (NCT00907205)Semafore Pharmaceuticals2007-04-01
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study (NCT00096941)Genentech, Inc.2005-05-01

Track Solid Cancers automatically

Every clearance here is in the API, with alerts when new ones post.